{"id":62624,"date":"2026-04-08T20:41:32","date_gmt":"2026-04-08T12:41:32","guid":{"rendered":"https:\/\/flcube.com\/?p=62624"},"modified":"2026-04-08T20:41:33","modified_gmt":"2026-04-08T12:41:33","slug":"takeda-terminates-neuroscience-partnership-with-denali-returns-frontotemporal-dementia-candidate-dnl593-for-strategic-realignment","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=62624","title":{"rendered":"Takeda Terminates Neuroscience Partnership with Denali, Returns Frontotemporal Dementia Candidate DNL593 for Strategic Realignment"},"content":{"rendered":"\n<p><strong>Takeda Pharmaceutical Company Limited (<a href=\"https:\/\/www.google.com\/finance\/quote\/4502:TYO\">TYO: 4502<\/a>, <a href=\"https:\/\/www.google.com\/finance\/quote\/TAK:NYSE\">NYSE: TAK<\/a>)<\/strong> announced the termination of its neuroscience collaboration with <strong>Denali Therapeutics Inc. (<a href=\"https:\/\/www.google.com\/finance\/quote\/DNLI:NASDAQ\">NASDAQ: DNLI<\/a>)<\/strong>, returning the frontotemporal dementia drug candidate <strong>DNL593<\/strong> to the US biotechnology company. The decision, described as <strong>purely strategic<\/strong>, follows the earlier discontinuation of their Alzheimer&#8217;s disease program in 2023 and reflects Takeda&#8217;s portfolio prioritization amid evolving neuroscience development challenges.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-partnership-timeline-amp-asset-details\">Partnership Timeline &amp; Asset Details<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Parameter<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Original Agreement<\/strong><\/td><td>2018 \u2013 Co-development of up to three neurodegenerative disease programs<\/td><\/tr><tr><td><strong>First Program (Discontinued)<\/strong><\/td><td>DNL919\/TAK-920 \u2013 TREM2-targeting antibody transport vehicle (ATV) for Alzheimer&#8217;s disease<\/td><\/tr><tr><td><strong>Discontinuation Reason<\/strong><\/td><td>Phase I safety concerns and limited therapeutic window (2023)<\/td><\/tr><tr><td><strong>Returned Asset<\/strong><\/td><td>DNL593 \u2013 Progranulin replacement therapy using protein transport vehicle (PTV) technology<\/td><\/tr><tr><td><strong>Indication<\/strong><\/td><td>Frontotemporal dementia with granulin mutation (FTD-GRN)<\/td><\/tr><tr><td><strong>Current Leadership<\/strong><\/td><td>Denali Therapeutics (sole development responsibility post-return)<\/td><\/tr><tr><td><strong>Termination Basis<\/strong><\/td><td>Strategic portfolio realignment, not safety or efficacy concerns<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-asset-profile-dnl593-progranulin-replacement-therapy\">Asset Profile: DNL593 Progranulin Replacement Therapy<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Mechanism<\/strong>: Investigational progranulin replacement therapy utilizing Denali&#8217;s proprietary <strong>protein transport vehicle (PTV)<\/strong> platform<\/li>\n\n\n\n<li><strong>Delivery Innovation<\/strong>: Engineered to cross the <strong>blood-brain barrier<\/strong> and deliver therapeutic progranulin directly to the brain<\/li>\n\n\n\n<li><strong>Target Population<\/strong>: Patients with <strong>frontotemporal dementia with granulin mutation (FTD-GRN)<\/strong>, a genetically defined subset of FTD<\/li>\n\n\n\n<li><strong>Development Stage<\/strong>: Preclinical\/early clinical (specific phase not disclosed)<\/li>\n\n\n\n<li><strong>Therapeutic Rationale<\/strong>: Addresses progranulin deficiency, a known causal factor in FTD-GRN pathogenesis<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-strategic-context-amp-portfolio-implications\">Strategic Context &amp; Portfolio Implications<\/h2>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-takeda-s-neuroscience-portfolio-evolution\">Takeda&#8217;s Neuroscience Portfolio Evolution<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Strategic Refocus<\/strong>: Decision aligns with Takeda&#8217;s broader portfolio optimization strategy in neuroscience<\/li>\n\n\n\n<li><strong>Resource Allocation<\/strong>: Enables reallocation of R&amp;D resources to higher-priority therapeutic areas<\/li>\n\n\n\n<li><strong>Risk Management<\/strong>: Reflects industry-wide challenges in neurodegenerative disease drug development<\/li>\n\n\n\n<li><strong>Partnership History<\/strong>: Represents conclusion of eight-year neuroscience collaboration initiated in 2018<\/li>\n<\/ul>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-denali-s-path-forward\">Denali&#8217;s Path Forward<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Sole Development Rights<\/strong>: Full control over DNL593 development and commercialization<\/li>\n\n\n\n<li><strong>Platform Validation<\/strong>: Continued advancement of PTV technology for CNS delivery<\/li>\n\n\n\n<li><strong>FTD-GRN Focus<\/strong>: Maintains commitment to genetically defined neurodegenerative disorders<\/li>\n\n\n\n<li><strong>Funding Considerations<\/strong>: May seek new partnership or additional capital to advance program<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-market-impact-amp-industry-trends\">Market Impact &amp; Industry Trends<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Neuroscience Investment Climate<\/strong>: Reflects cautious industry approach to high-risk, high-cost neurodegenerative disease programs<\/li>\n\n\n\n<li><strong>Blood-Brain Barrier Technologies<\/strong>: PTV platform represents one of several emerging approaches to CNS drug delivery<\/li>\n\n\n\n<li><strong>Genetically Targeted Therapies<\/strong>: FTD-GRN represents precision medicine approach in neurodegenerative diseases<\/li>\n\n\n\n<li><strong>Partnership Dynamics<\/strong>: Highlights evolving risk-sharing models in early-stage neuroscience collaborations<\/li>\n<\/ul>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-financial-amp-operational-considerations\">Financial &amp; Operational Considerations<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Takeda Impact<\/strong>: Minimal financial impact expected; no significant milestone payments or write-downs anticipated<\/li>\n\n\n\n<li><strong>Denali Impact<\/strong>: Regains full economic rights but assumes complete development costs and risks<\/li>\n\n\n\n<li><strong>Timeline Implications<\/strong>: Potential delay in DNL593 development pending Denali&#8217;s resource allocation decisions<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-competitive-landscape\">Competitive Landscape<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>FTD-GRN Pipeline<\/strong>: Limited competitive landscape with few companies targeting this specific genetic form of frontotemporal dementia<\/li>\n\n\n\n<li><strong>CNS Delivery Platforms<\/strong>: Competing technologies include focused ultrasound, nanoparticle delivery, and receptor-mediated transport systems<\/li>\n\n\n\n<li><strong>Progranulin Therapies<\/strong>: Alternative approaches include gene therapy and small molecule progranulin enhancers in earlier development<\/li>\n<\/ul>\n\n\n\n<p><strong>Forward-Looking Statements<\/strong><br>This brief contains forward-looking statements regarding partnership terminations, development timelines, and strategic decisions. Actual results may differ due to risks including regulatory requirements, clinical trial outcomes, and market conditions.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Takeda Pharmaceutical Company Limited (TYO: 4502, NYSE: TAK) announced the termination of its neuroscience collaboration&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,10],"tags":[1522,1521,874,345,1141],"class_list":["post-62624","post","type-post","status-publish","format-standard","hentry","category-company","category-deals","tag-denali-therapeutics","tag-nasdaq-dnli","tag-nyse-tak","tag-takeda","tag-tyo-4502"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.3) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Takeda Terminates Neuroscience Partnership with Denali, Returns Frontotemporal Dementia Candidate DNL593 for Strategic Realignment - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Takeda Pharmaceutical Company Limited (TYO: 4502, NYSE: TAK) announced the termination of its neuroscience collaboration with Denali Therapeutics Inc. (NASDAQ: DNLI), returning the frontotemporal dementia drug candidate DNL593 to the US biotechnology company. The decision, described as purely strategic, follows the earlier discontinuation of their Alzheimer&#039;s disease program in 2023 and reflects Takeda&#039;s portfolio prioritization amid evolving neuroscience development challenges.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=62624\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Takeda Terminates Neuroscience Partnership with Denali, Returns Frontotemporal Dementia Candidate DNL593 for Strategic Realignment\" \/>\n<meta property=\"og:description\" content=\"Takeda Pharmaceutical Company Limited (TYO: 4502, NYSE: TAK) announced the termination of its neuroscience collaboration with Denali Therapeutics Inc. (NASDAQ: DNLI), returning the frontotemporal dementia drug candidate DNL593 to the US biotechnology company. The decision, described as purely strategic, follows the earlier discontinuation of their Alzheimer&#039;s disease program in 2023 and reflects Takeda&#039;s portfolio prioritization amid evolving neuroscience development challenges.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=62624\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-04-08T12:41:32+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-04-08T12:41:33+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=62624#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=62624\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Takeda Terminates Neuroscience Partnership with Denali, Returns Frontotemporal Dementia Candidate DNL593 for Strategic Realignment\",\"datePublished\":\"2026-04-08T12:41:32+00:00\",\"dateModified\":\"2026-04-08T12:41:33+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=62624\"},\"wordCount\":506,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"Denali Therapeutics\",\"NASDAQ: DNLI\",\"NYSE: TAK\",\"Takeda\",\"TYO: 4502\"],\"articleSection\":[\"Company\",\"Deals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=62624#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=62624\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=62624\",\"name\":\"Takeda Terminates Neuroscience Partnership with Denali, Returns Frontotemporal Dementia Candidate DNL593 for Strategic Realignment - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2026-04-08T12:41:32+00:00\",\"dateModified\":\"2026-04-08T12:41:33+00:00\",\"description\":\"Takeda Pharmaceutical Company Limited (TYO: 4502, NYSE: TAK) announced the termination of its neuroscience collaboration with Denali Therapeutics Inc. (NASDAQ: DNLI), returning the frontotemporal dementia drug candidate DNL593 to the US biotechnology company. The decision, described as purely strategic, follows the earlier discontinuation of their Alzheimer's disease program in 2023 and reflects Takeda's portfolio prioritization amid evolving neuroscience development challenges.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=62624#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=62624\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=62624#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Takeda Terminates Neuroscience Partnership with Denali, Returns Frontotemporal Dementia Candidate DNL593 for Strategic Realignment\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Takeda Terminates Neuroscience Partnership with Denali, Returns Frontotemporal Dementia Candidate DNL593 for Strategic Realignment - Insight, China&#039;s Pharmaceutical Industry","description":"Takeda Pharmaceutical Company Limited (TYO: 4502, NYSE: TAK) announced the termination of its neuroscience collaboration with Denali Therapeutics Inc. (NASDAQ: DNLI), returning the frontotemporal dementia drug candidate DNL593 to the US biotechnology company. The decision, described as purely strategic, follows the earlier discontinuation of their Alzheimer's disease program in 2023 and reflects Takeda's portfolio prioritization amid evolving neuroscience development challenges.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=62624","og_locale":"en_US","og_type":"article","og_title":"Takeda Terminates Neuroscience Partnership with Denali, Returns Frontotemporal Dementia Candidate DNL593 for Strategic Realignment","og_description":"Takeda Pharmaceutical Company Limited (TYO: 4502, NYSE: TAK) announced the termination of its neuroscience collaboration with Denali Therapeutics Inc. (NASDAQ: DNLI), returning the frontotemporal dementia drug candidate DNL593 to the US biotechnology company. The decision, described as purely strategic, follows the earlier discontinuation of their Alzheimer's disease program in 2023 and reflects Takeda's portfolio prioritization amid evolving neuroscience development challenges.","og_url":"https:\/\/flcube.com\/?p=62624","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-04-08T12:41:32+00:00","article_modified_time":"2026-04-08T12:41:33+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=62624#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=62624"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Takeda Terminates Neuroscience Partnership with Denali, Returns Frontotemporal Dementia Candidate DNL593 for Strategic Realignment","datePublished":"2026-04-08T12:41:32+00:00","dateModified":"2026-04-08T12:41:33+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=62624"},"wordCount":506,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["Denali Therapeutics","NASDAQ: DNLI","NYSE: TAK","Takeda","TYO: 4502"],"articleSection":["Company","Deals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=62624#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=62624","url":"https:\/\/flcube.com\/?p=62624","name":"Takeda Terminates Neuroscience Partnership with Denali, Returns Frontotemporal Dementia Candidate DNL593 for Strategic Realignment - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2026-04-08T12:41:32+00:00","dateModified":"2026-04-08T12:41:33+00:00","description":"Takeda Pharmaceutical Company Limited (TYO: 4502, NYSE: TAK) announced the termination of its neuroscience collaboration with Denali Therapeutics Inc. (NASDAQ: DNLI), returning the frontotemporal dementia drug candidate DNL593 to the US biotechnology company. The decision, described as purely strategic, follows the earlier discontinuation of their Alzheimer's disease program in 2023 and reflects Takeda's portfolio prioritization amid evolving neuroscience development challenges.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=62624#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=62624"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=62624#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Takeda Terminates Neuroscience Partnership with Denali, Returns Frontotemporal Dementia Candidate DNL593 for Strategic Realignment"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/62624","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=62624"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/62624\/revisions"}],"predecessor-version":[{"id":62626,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/62624\/revisions\/62626"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=62624"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=62624"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=62624"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}